Treatment of hepatitis delta virus infection with interferon lambda

1. A method of treating a hepatitis delta virus (HDV) infection in a human patient, the method comprising administering to the patient a therapeutically effective amount of interferon lambda for at least four weeks, wherein the patient is not co-infected with hepatitis C virus (HCV), and wherein the patient exhibits no evidence of an alternative liver disease selected from the group consisting of autoimmune liver disease, primary bilary cirrhosis, primary sclerosing cholangitis, Wilson's disease, alcoholic liver disease, nonalcoholic steatohepatitis, and hemochromatosis.

2. The method of claim 1 , wherein the patient has compensated liver disease with or without cirrhosis.

3. The method of claim 2 , wherein the patient has compensated liver disease with cirrhosis.

4. The method of claim 1 , wherein the interferon lambda is pegylated.

5. The method of claim 4 , wherein the interferon lambda is pegylated interferon lambda-1a.

6. The method of claim 1 , wherein the interferon lambda is administered at a dose of 120 micrograms per week.

7. The method of claim 1 , wherein the interferon lambda is administered at a dose of 180 micrograms per week.

8. The method of claim 1 , wherein the interferon lambda is subcutaneously administered.

9. The method of claim 1 , wherein the interferon lambda is administered for at least 6 months.

10. The method of claim 1 , wherein the course of treatment results in an HDV viral load that is below 100 copies/mL serum or below 100 IU/mL serum.

11. The method of claim 10 , wherein the HDV viral load remains below 100 copies/mL serum or below 100 IU/mL serum for at least 12 weeks after the end of treatment.

12. The method of claim 1 , wherein the course of treatment results in an HDV viral load that is below the level of detection.

13. The method of claim 12 , wherein the HDV viral load remains below the level of detection for at least 12 weeks after the end of treatment.

14. The method of claim 1 , wherein prior to the onset of treatment, the patient has a serum alanine aminotransferase (ALT) level that is above the upper limit of normal (ULN), and the course of treatment results in an improvement in serum ALT level in the patient to a level that is within the ULN.

15. The method of claim 1 , wherein the course of treatment results in a reduction in HBV viral load in the patient as compared to the patient's baseline HBV viral load at the initiation of treatment.

16. The method of claim 1 , wherein the course of treatment results in improved liver function in the patient.

17. The method of claim 16 , wherein the improved liver function is an improvement in one or more serum markers selected from the group consisting of serum albumin, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin, alfa2-macroglobulin, apolipoproteinA1, haptoglobin, gamma-glutamyl transpeptidase (GGT).

18. The method of claim 16 , wherein the improved liver function is an improvement in liver fibrosis.

19. The method of claim 1 , wherein the method further comprises administering to the patient another antiviral or anti-HDV agent.

20. The method of claim 1 , wherein interferon lambda is the sole or primary antiviral treatment or the sole or primary anti-HDV agent.

21. The method of claim 1 , wherein the patient is not being treated with a CYP3A4 inhibitor.

22. The method of claim 1 , wherein the course of treatment results in an HDV viral load that is undetectable.

23. The method of claim 1 , wherein the course of treatment results in a reduction in HDV viral load in the patient of at least 1.5 log HDV RNA copies/mL compared to a baseline HDV viral load.

24. The method of claim 1 , wherein the patient has a baseline HDV viral load of at least 10 2 HDV RNA copies/mL serum at the initiation of treatment.